Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2004American Journal of HematologyOpen Access

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLydia KoulovaNew York Medical CollegeDADoru T AlexandrescuWestern UniversityJDJanice P. DutcherLung Cancer Research Foundation

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Koulova et al. (2004) studied this question.

synapsesocial.com/papers/6a754f181078cf7de2b2099chttps://doi.org/10.1002/ajh.20243
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab treatment results in impaired secondary humoral immune responsiveness2002 · 282 citations
  2. 2CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma2002 · 5,635 citations
  3. 3IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.1997 · 644 citations
  4. 4von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome1998 · 1,674 citations
  5. 5Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network2003 · 353 citations